Excellent presentation by Professor Erin Michos @erinmichos.bsky.social at #AHA25

Congratulations to our @hopkinsheart.bsky.social research fellow Dr @zaibhussain10.bsky.social on being a #QCOR Early Career Finalist at #AHA2025 ! 👏👏Check out her presentation Friday with simultaneous publication in Circ Outcomes on motivational themes for CV trial enrollment.

🚨 Don’t miss the Early Career Investigators Session #AHA2025! Groundbreaking @hopkinsheart.bsky.social research on maternal mortality and CVD risk to be featured w/ simultaneous pub in Circulation. Congrats to coauthors and Hopkins team lead by Anum Minhas and Theresa Boyer @erinmichos.bsky.social

FINE-ONE was just presented at @asnkidney.bsky.social at #KidneyWk. #Finerenone significantly reduced #UACR by 25% at 6 months in patients with #T1D & #CKD - an understudied population with high unmet need.

Pleased to take part in this podcast about "Diagnostic Strategies for the Timely Detection of Familial Chylomicronemia Syndrome" with Dr Archna Bajaj. #FCS #lipids Sponsored by @vindicomeded.bsky.social & @gohealio.bsky.social www.healio.com/cme/mededtal...

Great @hopkinsheart.bsky.social representation @ase360.bsky.social @mmukherjeemd.bsky.social @erinmichos.bsky.social

Excellent session on women’s heart health across the lifespan and role of Echo at #ASE2025 Featuring @erinmichos.bsky.social (women’s health leader @HopkinsHeart) @anabarac (pioneer in cardio-oncology), masterfully chaired by @sharonmulvagh expert in Echo and women’s CV health

New study alert: Women with established coronary artery disease are less likely than men to receive guideline-based statin therapy—and face higher rates of recurrent cardiovascular events. Ensuring equal treatment equity could save more lives. Read more: www.sciencedirect.com/science/arti...

Changes in #BoneMineralDensity were mediated by changes in E2 and testosterone among women and men, respectively, with #T2D undergoing weight loss. @erinmichos.bsky.social @johnshopkinssph.bsky.social @jhu.edu @imperialcollegeldn.bsky.social @uthsc.bsky.social

For patients who can’t tolerate statins, or need more LDL-C lowering despite high-intensity therapy, bempedoic acid is a proven option that’s often overlooked. @erinmichos.bsky.social @ciccaronecenter.bsky.social Quick read our case 🔗 @accintouch.bsky.social learn.acc.org/Page/Bempedo...

📢 New in AJPC: Study explores how gender and menopause status impact BP reduction in a mobile health self-management program for hypertension. @drmarthagulati.bsky.social @erinmichos.bsky.social 📱💡 Personalized care matters. ow.ly/H8ob50WrnQk #Hypertension #Cardiology #mHealth #AJPC

We’re proud to celebrate @ajpcardio.bsky.social — official journal of the ASPC — on its 2024 impact factor of 5.9 & ranking 34 of 230 journals in Cardiac & Cardiovascular Systems! Kudos Dr. Nathan Wong, @erinmichos.bsky.social, & the AJPC community for advancing the field of preventive cardiology.

Having a great time and learning a ton at the @nationaljewish.org CV Symposium: Improving Cardiovascular Outcomes: The Next Era of Prevention. AND I got to see Dr. @erinmichos.bsky.social and ask her all my pressing cardiology questions. 🫀❤️👊

The impact of federal actions on academic medicine and the U.S. health care system www.aamc.org/about-us/aam... @cardioobdoc.bsky.social @arghavansallesmd.medsky.social @erinmichos.bsky.social @drmarthagulati.bsky.social

Systemic review of discordance studies by Daniel Sehayek, et al. finds apoB generally outperforms LDL-C and non-HDL-C. (prior post of recent study adds to this evidence) #cardiosky www.lipidjournal.com/article/S193...

June 2025 #AJPC Editors’ Message @erinmichos.bsky.social & Dr. Nathan Wong! Dive into cutting-edge articles on AI, psychosocial stress, obesity, chylomicronemia, and more in #CVDPrevention. Plus, a preview of #ASPC2025! www.sciencedirect.com/science/arti... #CardioSky @aspcardio.bsky.social

New at #HiD25: @erinmichos.bsky.social, director of women's cardiovascular health at Johns Hopkins University, met with us to discuss her presentation on postmenopausal hormone imbalance, obesity, and cardiovascular disease risk in women. Watch the interview here: www.hcplive.com/view/post-me...

A huge congratulations to our Cardiology Fellowship APD, Dr. Anum Minhas, who was awarded the Young Author Achievement Award for @jaccjournals.bsky.social JACC Advances 💖

🍳 FREE CME + breakfast + the latest breakthroughs in #ASCVD treatment Fri, May 30 | 7:15–8:45 AM at JW Marriott Miami Turnberry Resort and Spa #NLASessions 🔗 vindicoce.com/NLA @nationallipid.bsky.social @erinmichos.bsky.social @foundationofnla.bsky.social @lipidjournal.bsky.social

Don’t miss the CETP comeback story—plus RAPID-FIRE ROUNDTABLE—at our CE breakfast on May 30 during #NLASessions Register here >> vindicoce.com/NLA @erinmichos.bsky.social @nationallipid.bsky.social @lipidjournal.bsky.social @foundationofnla.bsky.social

Pleased to be a co-author of this study and part of TANDEM steering committee. Given the critical importance of reducing LDL Cholesterol for preventing atherosclerotic cardiovascular disease, more options to lower LDL-C is a good thing!

Long-term trials of #colchicine for secondary prevention of vascular events: a meta-analysis #CardioSky academic.oup.com/eurheartj/ad... @escardio.bsky.social @anastasiasmihaili.bsky.social @victoriadelgadomd.bsky.social @gimelliale.bsky.social @load-dependent.bsky.social @dmljmd.bsky.social

Join me in Nashville Sept 5-7 for the American Society of Echocardiography @ase360.bsky.social Scientific Sessions and 50th year Anniversary! Join us for late breaking innovations & updates in cardiovascular ultrasound. #echofirst #ASE2025 #EchoSky

Just finished up a great 2 days of learning & developing solutions for better heart health for women at Hello Heart’s 2nd annual conference. Rock star faculty & engaged participants. @erinmichos.bsky.social @jaynemorgan.bsky.social @womenheart.bsky.social

Exciting news for #liver health! The #GLP1RA #semaglutide significantly improved #MASH & fibrosis.

@eassociety.bsky.social #EASCongress2025 #lipids #obicetrapib

In a randomized trial of patients at high cardiovascular risk, the cholesteryl ester transfer protein inhibitor obicetrapib reduced low-density lipoprotein cholesterol levels by 29.9% at 84 days. Full BROADWAY trial results: nej.md/4lKsmMK @eassociety.bsky.social | #EASCongress2025

Pleased to share our results from the TANDEM Trial published in @thelancet.bsky.social today and presented at EAS: Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction: a phase 3, randomised, double-blind, placebo-controlled trial www.thelancet.com/journals/lan...

Excited to be a part of #NLASessions! We're bringing an exciting #CE breakfast symposium on CETP inhibitors on Fri 5/30. Register here: vindicoce.com/NLA #ASCVD #lipid #lipidology #cardiovasculardisease #dyslipidemia #MedSky @nationallipid @Lipidjournal @Foundationofnla @erinmichos.bsky.social

Congratulations, Dr. Michos, on receiving such a well-deserved recognition! @erinmichos.bsky.social

Congratulations to @erinmichos.bsky.social on being a recipient of the @hopkinsmedicine.bsky.social Susan M. MacDonald Sponsorship Award! @ciccaronecenter.bsky.social

New @aspcardio.bsky.social Clinical Practice Statement🫀: Framework to improve cardiometabolic care for South Asians—individual to population level. ow.ly/glCT50VGq9Y @pnatarajanmd.bsky.social @drmarthagulati.bsky.social #CardioSky #MedSky #SouthAsianHealth #HeartHealth #ASPC

Register for #NLASessions to join! 🔗 lipid.org/sessions

Honored to speak at UKRAINE & EUROPE: UNITING HEARTS, organized by Ukrainian Atherosclerosis Society. I was deeply moved to join as an online speaker to support Ukrainian Colleagues during the most difficult circumstances. @eassociety.bsky.social @erinmichos.bsky.social

Please to share our state of the art review on "Sex Hormones and Heart Failure Risk" in @jaccjournals.bsky.social #JACCAdv led by Dr. Imo Ebong. Find it here at: www.jacc.org/doi/10.1016/...

I'm excited to be a part of "Lowering LDL-C: The Role of Emerging CETP Inhibitors in Reducing CV Risk on 5/30/2025" at @nationallipid.bsky.social Scientific Sessions. Activity agenda & registration can be found here: events.vindicocme.com/15kYU86/5a2B... @vindicomeded.bsky.social #lipids #CME

Huge congratulations Dr Anum Minhas! @hopkinsheart.bsky.social #ACC25 #CardioOb 🎉🎉👏👏

CONFIRM-II: #AI-QCT Assessment of Coronary Plaque Feature Confers Higher Relative Risk of MACE in Women Read the journal scan to learn more: bit.ly/4layvBv #ACC25 #CardioSky #MedSky

At #ACC25, Dr. Michael J. Koren & colleagues present the results of PURSUIT, which found that a novel oral #PCSK9i achieved LDL reductions on top of background statin therapy with a similar side effect profile to placebo jacc.org/doi/10.1016/... #JACC

Exciting new development in lipid field! The early Phase 2 #PURSUIT trial showed a novel oral #PCSK9i (that can be taken with food) lowered LDL-C by 51% at 12 weeks. 84% achieved LDL-C of <70 mg/dL. #ACC25 @accintouch.bsky.social

Dr. Nissen presents #ALPACA assessing siRNA in ⬇️ Lp(a) Lepodisiran ♥️400 mg dose: 95% ⬇️, sustained 180 days but still effects after at 540 days ♥️ Large ⬇️ in Lp(a) ♥️ ApoB ⬇️ by 15% ♥️ safety favorable: 1 withdrew in placebo #ACC25 #CVPrev @nejm.org 📎 www.nejm.org/doi/full/10....

Happy to catch up with the Hopkins Ciccarone Center Prevention Fellows at the #ACC25 Women in Cardiology networking event. Packed room of women, ready to take #ACTION against #CVD. @accintouch.bsky.social @hopkinsheart.bsky.social @ciccaronecenter.bsky.social

#ExpectMoreForLDL. Working together towards combating #ASCVD, the leading cause of morbidity & mortality. Exciting new options for LDL-C lowering. #ACC25 @newamsterdampharma.bsky.social

DAPA-TAVI: The #SGLT2 inhibitor dapagliflozin was superior to standard care alone in decreasing rates of all-cause mortality or worsening #HeartFailure in older adults w/ #vhdAS undergoing TAVI, resulting in a 28% relative risk ↘️. #ACC25 More: bit.ly/4cfLNsy #cvSurg #CardioSky #MedSky

An oral formulation of semaglutide lowered the risk major adverse cardiovascular events by 14% in four years, with no change in safety profile compared to placebo, according to the SOUL study. #ACC25 Read the journal scan to learn more: bit.ly/3QTpizK #CardioSky #MedSky

#SOUL trial presented at #ACC25. Oral #semaglutide reduced 3-pt major adverse cardiovascular events by 14% in patients with T2D, even with high background SGLTi use. In exploratory analysis, oral sema also reduced major limb events. #CardioSky @accintouch.bsky.social

The STRIDE trial demonstrated that semaglutide significantly improves function, symptoms, and health-related QoL in patients with symptomatic #cvPAD and T2DM. Get the full clinical trial details here ➡️ bit.ly/42dnA1n #ACC25 #CardioSky #MedSky

Exciting! #STRIDE trial just presented at #ACC25 @accintouch.bsky.social . #Semaglutide improved mean walking distance, symptoms, major limb events & quality of life in patients with #T2D & #PAD. We have a new drug now to help PAD patients! #CardioSky

Read the joint Consensus from @aspcardio.bsky.social & @nationallipid.bsky.social! Recognition & Management of Persistent Chylomicronemia: A comprehensive expert clinical consensus by the NLA & ASPC. ow.ly/NU9g50VqxCE @michaeldshapiro.bsky.social @erinmichos.bsky.social #NationalTriglyceridesDay

Very pleased to be part of this important joint scientific statement between the #NLA & #ASPC on Persistent Chylomicronemia. #lipids #triglycerides